Kim R. Tsuchimoto - 30 Jun 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Financial Officer, Director
Signature
/s/ Karthik Radhakrishnan ,Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
30 Jun 2024
Net transactions value
-$2,192
Form type
4
Filing time
02 Jul 2024, 18:08:53 UTC
Previous filing
02 Apr 2024
Next filing
07 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +9,957 +20% 60,427 30 Jun 2024 Direct F1
transaction MNPR Common Stock Tax liability $2,192 -2,998 -5% $0.7310 57,429 30 Jun 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -9,957 -12% $0.000000 74,412 30 Jun 2024 Common Stock 9,957 Direct F1, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3 On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F4 On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5 On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.